Expert Insights on Highlights From ASH 2020 on Lymphomas/CLL - a podcast by Clinical Care Options
from 2021-03-26T20:30
In this episode, Jeremy S. Abramson, MD, MMSc, discusses highlights of the key data from ASH 2020 on the treatment of patients with lymphomas/CLL, with topics including:
- Approved and Investigational Targeted Therapeutics for CLL
- Investigational CAR T-Cell Therapy for Indolent Lymphomas, CLL, and Mantle Cell Lymphoma
- Bispecific Antibodies and Other Investigational Targeted Agents for Lymphomas
- Treatment for Older Patients With Hodgkin Lymphoma
Presenters:
Jeremy S. Abramson, MD, MMSc
Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts
Content based on an online CME program supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology.
Link to full program:
https://bit.ly/3tyQ9nG
Further episodes of CCO Oncology Podcast
Further podcasts by Clinical Care Options
Website of Clinical Care Options